pipette
ENEnglish

Early potassium response to mineralocorticoid receptor antagonist therapy and cardiovascular outcomes in primary aldosteronism: a landmark cohort study

S.-H. Chen, Y. H. Huang, Y.-H. Lee, S.-M. Yang, C.-J. Huang, Y.-K. Pang, Y.-Y. Chen, H.-M. Cheng

PreprintUso en el mundo real

En palabras de los autores

Background Mineralocorticoid receptor antagonists (MRAs) are standard therapy for primary aldosteronism (PA). Serum potassium is measured in nearly every treated patient, but the long-term prognostic value of potassium attained early after initiation is undefined. Methods In the TriNetX Research Network, we identified adults with PA newly initiating spironolactone or eplerenone in 2000-2025, without prior adrenalectomy (n=4,169; 180-day landmark design). Achieved potassium (last value on days 14-180) was categorised as <4.0, 4.0-<4.5, 4.5-<5.0 and [&ge;]5.0 mmol/L, and its change from baseline in tertiles, using cause-specific Cox and Fine-Gray models. The primary outcome was a composite of myocardial infarction, stroke or death; incident heart failure was co-primary. Findings Over a median 3.0 years, 623 composite events occurred. Estimated risk was lowest at 4.5-<5.0 mmol/L (adjusted hazard ratio 0.65, 95% CI 0.52-0.83, versus <4.0 mmol/L), lower than the 4.0-<4.5 mmol/L band, and not different from [&ge;]5.0 mmol/L. A larger rise in potassium was associated with lower risk. A similar pattern was seen for incident heart failure (0.54, 0.36-0.80; 248 events). Potassium below the 3.6 mmol/L consensus threshold for hypokalaemia carried no significantly higher risk (1.22, 0.96-1.56). The change in potassium correlated weakly with the change in renin (rho = 0.15). Interpretation In MRA-treated PA, cardiovascular and heart-failure risk was lowest at an early achieved potassium of 4.5-<5.0 mmol/L, well above the 3.6 mmol/L accepted by consensus criteria as correction of hypokalaemia; correction alone may therefore be an insufficient treatment target. Whether titrating therapy towards this band improves outcomes requires prospective evaluation.

Resultado principalLimitación que admiten los autores

Apareció: miércoles, 18 de noviembre. medRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.11.15.26368152